当前位置： SCI文献检索 > EPILEPSY RESEARCH期刊下所有文献 > Higher androgens and weight gain with valproate compared with lamotrigine for epilepsy.

Higher androgens and weight gain with valproate compared with lamotrigine for epilepsy.

Abstract：

BACKGROUND:Valproate is used widely for the treatment of epilepsy but has been associated with hyperandrogenism, hyperinsulinemia, and dyslipidemia. The mechanism for these associations is unknown, but they have been hypothesized to be secondary to valproate-associated weight gain. This study was conducted to test the hypothesis that the antiepileptic drug lamotrigine, which also has a broad spectrum of anti-seizure efficacy, would not be associated with endocrine abnormalities and would not cause weight gain. OBJECTIVE AND METHODS:This open-label, cross-sectional study compared (1) endocrine and lipid measures during the early follicular phase of the menstrual cycle; (2) prevalence of menstrual disorders (from patient diaries recorded over three cycles); and (3) body weight of women with epilepsy on lamotrigine monotherapy (n=119) with those on valproate monotherapy (n=103) for <5 years. RESULTS:Mean total serum testosterone and androstenedione levels were higher (P<0.02) in the valproate group compared with the lamotrigine group. More lamotrigine patients (87%) than valproate patients (77%) reported regular menstrual cycles at the Screening Visit. The prevalence of anovulation did not differ between lamotrigine and valproate. Mean HDL cholesterol levels were higher (P<0.01) with lamotrigine compared with valproate as were LDL and total cholesterol levels (P<0.05). Mean total insulin levels did not significantly differ between the groups. Whereas mean body weight in lamotrigine patients did not differ between the time lamotrigine treatment was initiated and the Study Visit, mean weight in valproate patients increased by 3.7 kg. CONCLUSIONS:Compared with lamotrigine monotherapy, valproate monotherapy was associated with weight gain and higher androgen levels in women with epilepsy. These data suggest that the hyperandrogenism observed in some women using valproate for epilepsy may be secondary to drug therapy. Lamotrigine monotherapy may be more appropriate than valproate for women in whom reproductive endocrine or metabolic abnormalities are potential concerns, i.e. women with concerns about weight gain, diabetes, hirsutism, polycystic ovary syndrome, menstrual dysfunction or infertility.

journal_name

Epilepsy Res

journal_title

Epilepsy research

authors

Morrell MJ,Isojärvi J,Taylor AE,Dam M,Ayala R,Gomez G,O'Neill F,Tennis P,Messenheimer J

doi

10.1016/s0920-1211(03)00085-8

subject

Has Abstract

pub_date

2003-05-01 00:00:00

pages

189-99

issue

2-3

eissn

0920-1211

issn

1872-6844

pii

S0920121103000858

journal_volume

pub_type

杂志文章,多中心研究

在线工具

Higher androgens and weight gain with valproate compared with lamotrigine for epilepsy.